Skip to main content
Premium Trial:

Request an Annual Quote

New Fundings Hold Steady From May to June

NEW YORK, July 2 – The number of new funding deals did not change significantly from May to June, a report released Monday by Facts Online said.

During the month of June the number of fundings was at 306, nearly identical to 309 in May. In April 325 companies received funding.

“It’s encouraging that it’s stable in light of all the gnashing of teeth about the downturn in the economy,” said Harry Henry, chief operating officer of Facts Online, which tracks funding trends. “It’s not as robust as last year [at this time], but we’re not in a downward spiral.”

The survey includes all funding deals stemming from venture capital, investments by other companies, initial public offerings, private placements, new bond issues, and increases in lines of credit. 

Fundings for companies in the pharmaceutical, biotech, and health devices category represented 15 percent of the total deals. Software companies dominated the fundings, representing 32.9 percent of the deals.

Of the companies funded, 79.4 percent were privately owned. Of the public companies, the highest percentage, 14.4 percent, were listed on Nasdaq.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.